Dianne Angus - Neuren Pharmaceuticals Non-Executive Independent Director
| NURPF Stock | USD 12.51 0.02 0.16% |
Director
Ms. Dianne Angus is NonExecutive Independent Director of the Company. Dianne Angus is currently interim CEO of the Victorian Australian Medical Association and was formerly Chief Operating Officer of the neurological drug development company Prana Biotechnology. Dianne is also a registered Patent and Trademark Attorney. since 2018.
| Tenure | 6 years |
| Phone | 61 3 9092 0480 |
| Web | https://www.neurenpharma.com |
Neuren Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.172) % which means that it has lost $0.172 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2746) %, meaning that it generated substantial loss on money invested by shareholders. Neuren Pharmaceuticals' management efficiency ratios could be used to measure how well Neuren Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| David Barrett | Fortress Biotech Pref | 39 | |
| Kevin Lorenz | Fortress Biotech Pref | N/A | |
| Soeren Pedersen | Novo Nordisk AS | 52 | |
| Liz Hewitt | Novo Nordisk AS | 64 | |
| Eivind Kolding | Novo Nordisk AS | 55 | |
| Malcolm Hoenlein | Fortress Biotech Pref | 73 | |
| Sylvie Gregoire | Novo Nordisk AS | 59 | |
| Peter Kiener | GT Biopharma | 63 | |
| Stig Stroebaek | Novo Nordisk AS | 55 | |
| Thomas Rantzau | Novo Nordisk AS | 46 | |
| Mette Jensen | Novo Nordisk AS | 45 | |
| Martin Mackay | Novo Nordisk AS | 64 | |
| Jay Lobell | Fortress Biotech Pref | 51 | |
| Jimmie Harvey | Fortress Biotech Pref | 62 | |
| Brian Daniels | Novo Nordisk AS | 61 | |
| Anne Kverneland | Novo Nordisk AS | 64 | |
| Liselotte Hyveled | Novo Nordisk AS | 51 | |
| Mary Szela | Novo Nordisk AS | 52 | |
| Laurence Debroux | Novo Nordisk AS | 51 | |
| John Bonfiglio | GT Biopharma | 60 | |
| Geoffrey Davis | GT Biopharma | N/A | |
Management Performance
| Return On Equity | -0.27 | |||
| Return On Asset | -0.17 |
Neuren Pharmaceuticals Leadership Team
Elected by the shareholders, the Neuren Pharmaceuticals' board of directors comprises two types of representatives: Neuren Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neuren. The board's role is to monitor Neuren Pharmaceuticals' management team and ensure that shareholders' interests are well served. Neuren Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neuren Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph Horrigan, VP of Clinical Devel. and Medical Affairs | ||
| Larry Glass, CEO, Managing Director | ||
| Bruce Hancox, Independent Non-Executive Director | ||
| James Shaw, COO | ||
| Patrick Davies, Non-Executive Independent Director | ||
| Lauren CA, CFO Sec | ||
| Richard Treagus, Executive Chairman of the Board | ||
| Jon Pilcher, CFO, Company Secretary | ||
| Jenny Harry, Non-Executive Independent Director | ||
| Dianne Angus, Non-Executive Independent Director | ||
| ACA ACA, MD CEO | ||
| Gerry Zhao, VP Devel | ||
| Liza MD, Chief Officer | ||
| Trevor Scott, Independent Non-Executive Director | ||
| Lawrence Glass, Chief Officer |
Neuren Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Neuren Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.27 | |||
| Return On Asset | -0.17 | |||
| Profit Margin | (2.15) % | |||
| Operating Margin | (2.31) % | |||
| Current Valuation | 602.02 M | |||
| Shares Outstanding | 128.97 M | |||
| Shares Owned By Insiders | 16.48 % | |||
| Shares Owned By Institutions | 9.41 % | |||
| Price To Earning | 49.75 X | |||
| Price To Book | 27.96 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Neuren Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Neuren Pharmaceuticals' short interest history, or implied volatility extrapolated from Neuren Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuren Pharmaceuticals Limited. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Neuren Pink Sheet analysis
When running Neuren Pharmaceuticals' price analysis, check to measure Neuren Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuren Pharmaceuticals is operating at the current time. Most of Neuren Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Neuren Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuren Pharmaceuticals' price. Additionally, you may evaluate how the addition of Neuren Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |